115 related articles for article (PubMed ID: 12610502)
21. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M
Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic value of DNA ploidy and nuclear morphometry in metastatic prostate cancer].
Martínez Jabaloyas JM; Jiménez Sánchez A; Ruiz Cerdá JL; Sanz Chinesta S; Sempere A; Jiménez Cruz JF
Actas Urol Esp; 2004 Apr; 28(4):298-307. PubMed ID: 15248401
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy.
Nakashima J; Ozu C; Nishiyama T; Oya M; Ohigashi T; Asakura H; Tachibana M; Murai M
Urology; 2000 Nov; 56(5):843-7. PubMed ID: 11068314
[TBL] [Abstract][Full Text] [Related]
24. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.
Pollen JJ; Witztum KF; Ashburn WL
AJR Am J Roentgenol; 1984 Apr; 142(4):773-6. PubMed ID: 6230903
[TBL] [Abstract][Full Text] [Related]
25. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis.
Naruse K; Yamada Y; Aoki S; Taki T; Nakamura K; Tobiume M; Zennami K; Katsuda R; Sai S; Nishio Y; Inoue Y; Noguchi H; Hondai N
Hinyokika Kiyo; 2007 May; 53(5):287-92. PubMed ID: 17561711
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.
Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L
Br J Cancer; 2005 Sep; 93(6):633-8. PubMed ID: 16222309
[TBL] [Abstract][Full Text] [Related]
27. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
Wang ZL; Wang XF
Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960
[TBL] [Abstract][Full Text] [Related]
28. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2.
Jørgensen T; Kanagasingam Y; Kaalhus O; Tveter KJ; Bryne M; Skjørten F; Berner A; Danielsen HE
J Urol; 1997 Jul; 158(1):164-70. PubMed ID: 9186346
[TBL] [Abstract][Full Text] [Related]
30. Clinical study on prognosis of metastatic prostate cancer based on extent of disease on pretreatment bone scintigraphy.
Fuse H; Mizuno I; Yokoyama T; Sakamoto M; Katayama T
Int Urol Nephrol; 1995; 27(5):567-74. PubMed ID: 8775041
[TBL] [Abstract][Full Text] [Related]
31. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
Kosuda S; Yoshimura I; Aizawa T; Koizumi K; Akakura K; Kuyama J; Ichihara K; Yonese J; Koizumi M; Nakashima J; Fujii H
Cancer; 2002 Feb; 94(4):964-72. PubMed ID: 11920464
[TBL] [Abstract][Full Text] [Related]
32. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
33. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
34. [Correlation between bone gammagraphy and biochemical parameters in bone turnover in patients with prostate cancer].
Alcover J; Fernández-Conde M; Filella X; de Osaba MJ; Carretero P
Actas Urol Esp; 1994 Jun; 18(6):623-7. PubMed ID: 7524277
[TBL] [Abstract][Full Text] [Related]
35. [Stage M1b prostatic adenocarcinoma: prognostic factors, value of bone scintigraphy].
Rattier C; Rossi D; Coulange C; Rampal M; Serment G
Prog Urol; 1994 Dec; 4(6):984-99. PubMed ID: 7874187
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of bone-specific alkaline phosphatase for bone metastases detection in prostate cancer].
Rasch-Isla Muñoz A; Cataño Cataño JG
Arch Esp Urol; 2004 Sep; 57(7):693-8. PubMed ID: 15536950
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases.
Colombel M; Eaton CL; Hamdy F; Ricci E; van der Pluijm G; Cecchini M; Mege-Lechevallier F; Clezardin P; Thalmann G
Prostate; 2012 May; 72(7):713-20. PubMed ID: 21882211
[TBL] [Abstract][Full Text] [Related]
38. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
40. Tissue factor expression and prognosis in patients with metastatic prostate cancer.
Akashi T; Furuya Y; Ohta S; Fuse H
Urology; 2003 Dec; 62(6):1078-82. PubMed ID: 14665359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
